Impaired Relaxation in Aorta from Streptozotocin-diabetic Rats: Effect of Aminoguanidine (AMNG) Treatment

SIBEL ÖZYAZGAN, YESIM UNLUCERCI, SELDA BEKPINAR and AHMET GÖKHAN AKKAN*

University of Istanbul, Cerrahpasa Faculty of Medicine, Department of Pharmacology, 34303, Istanbul, Turkey

(Received 27 September 1999; In final form 10 February 2000)

Aim The effect of 8 weeks' streptozotocin (STZ)-induced diabetes and aminoguanidine (AMNG), the inhibitor of advanced glycosylation reaction, treatment on arteriolar reactivity to vasoactive substances was investigated in vitro.

Materials and Methods Studies were performed in untreated control rats (n=10), STZ-induced (60 mg/kg i.v.) diabetic rats (n=10), AMNG-treated (600 mg/l given in drinking water throughout 8 weeks) control rats (n=10) and AMNG-treated (600 mg/l given in drinking water, beginning at 72h after STZ and throughout 8 weeks of diabetes) diabetic rats (n=10).

Results are expressed as the mean ± s.e. Relaxant responses are expressed as a percentage (%) relaxation of noradrenaline-induced tone. Statistical comparisons were made by one-way analysis of variance (ANOVA) followed by Tukey – Kramer multiple comparisons test.

Results 1. The decreased body weights (205 ± 6 g) and increased blood glucose levels (583 ± 8 mg/dl) of diabetic rats were partially restored by treatment of aminoguanidine (253 ± 6 g, p < 0.05 and 480 ± 14 mg/dl, p < 0.001, respectively). 2. Diabetes caused a 71% deficit in maximal endothelium-dependent relaxation to acetylcholine for noradrenaline precontracted aortas (p < 0.001). AMNG treatment prevented the diabetes-induced impairment in endothelium dependent relaxation (58 ± 8%) to acetylcholine, maximum relaxation remaining in the non-diabetic range (78 ± 4%). 3. Neither diabetes nor treatment affected endothelium-independent relaxation (pD2 and max. Relax.) to sodium nitroprusside. 4. Vasoconstrictor responses (pD2 and Max. Contraction) to noradrenaline and KCl were not influenced by the diabetic state and treatment.

Conclusion Our data suggest that 8 weeks of experimental diabetes is associated with a decreased endothelium-dependent vasodilatation. AMNG treatment may prevent diabetes-induced endothelial dysfunction. This may be mediated via the prevention of advanced glycosylation end product formation, the enhanced release of vasodilator substances such as prostacyclin, the increased elasticity of blood vessels, the antioxidant activity and inhibitor activity of enzyme aldose-reductase by AMNG.

Keywords: Diabetes, aorta, streptozotocin, aminoguanidine, endothelium

INTRODUCTION

Hyperglycaemia is the primary cause of diabetic micro and macrovascular complications. Several major mechanisms have been proposed for hyperglycaemia-induced tissue damage, including advanced glycation end product...
(AGE) formation, altered intracellular redox state, increased polyol pathway flux, apoptosis and increased de novo diacylglycerol synthesis with resultant activation of protein kinase C isoform. [3–7]

Studies on vascular reactivity using the STZ-diabetic rat have reported inconsistent results with increased, decreased and unchanged responsiveness to noradrenaline, KCl, acetylcholine and sodium nitroprusside. [10–14]

Today, in addition to the prevention of hyperglycaemia by use of insulin and oral hypoglycaemic agents, it has been also used and tested some agent such as aminoguanidine for the prevention and treatment of complications in Diabetes Mellitus. Aminoguanidine is a small, hydrazine compound structurally identical to the amino-terminal group of arginine and several laboratories have reported beneficial effects of aminoguanidine in some diabetic complications. The mechanisms for these effects of AMNG were accompanied by reduction of advanced glycation end product (AGE) formation, the inhibition of an isoform of nitric oxide synthase (iNOS) and reactive oxygen species (ROS) formation, lipid peroxidation and oxidant-induced apoptosis. [15–18]

The present study was designed to define whether AMNG has beneficial effects on altered vascular reactivity of the thoracic aortas in streptozotocin-diabetic rats.

MATERIALS AND METHODS

Animals

Albino Wistar rats were bred in our laboratory and nourished ad libitum with standard pellet diet and had free access to tap water. Adult male and female Wistar rats (n = 40), weighing 200–300 g, were divided into four groups:

(i) Normal Control (= NC) (n = 10),
(ii) STZ-diabetic group (= DC) (n = 10),
(iii) AMNG-treated control group (AG−C) (n = 10),
(iv) AMNG-treated diabetic group (AG + D) (n = 10).

Induction of Experimental Diabetes

Rats were injected intravenously (into the lateral tail vein) with STZ (60 mg/kg)(Sigma, S-0130, Lot. 128H1045). STZ was freshly prepared in 0.25 ml saline. The rats were then maintained for 8 weeks with free access to food and water. Duration of the experimental period, blood glucose levels and body weights were measured beginning from 8th week.

Aminoguanidine Treatment

The rats in group III (AMNG-treated control group) and group IV (AMNG-treated STZ-diabetic group) were given 600 mg/l AMNG in drinking water (in group AG + D, beginning at 72h after STZ) for 8 weeks. The dosage in the drinking water was three times lower for the diabetic animals because their water intake is three times higher than that of nondiabetic animals. [45] In the dosage calculation, followed formula was used:

\[
\frac{\text{[(mg AG in per ml drinking water} \times \text{ml daily water intake)]} \times \left(\frac{1000}{\text{body weight}}\right)}{\text{}}
\]

Aortic Strips

Rats were sacrificed by stunning followed by decapitation. A segment (3–5 cm) of thoracic aorta was removed and placed in an ice-cold Krebs–Ringer solution (KRS) of the following composition (mmol/L): NaCl (118), KCl (4.7), CaCl₂ (2.5), MgSO₄·7H₂O (1.2), KH₂PO₄ (1.2), NaHCO₃ and glucose (11.1) and then trimmed free of adhering fat and connective tissue and cut into rings of 3 mm width. The rings were opened by cutting the vessels longitudinally. Subsequently, they were fixed with stainless steel clips at both ends and then placed in 20 ml
organ baths containing KRS, gassed with carbogen (95% $\text{O}_2 + 5\% \text{CO}_2$) providing pH 7.4 at 37°C. The preparation were connected to isometric force displacement transducer (MAY, FDT 10-A isometric transducer) connected to MAY, TDA 97 polygraph and were equilibrated for 90 min at optimal resting tension of 2 g. During this time, the KRS in the organ bath was replaced every 20 min.

**Concentration-response Curves**

After equilibration, the thoracic aorta strips were exposed to $10^{-5}$ mol/L (≈ EC$_{90}$) noradrenaline until the contraction reached the plateau (approximately 15 min) in order to measure the fast and slow components of vascular response to noradrenaline. The fast component was measured from the baseline to the point at which the rate of contraction started to decrease abruptly. The slow component was measured from this point to the top of the contraction. The total response was the sum of these two components. [16] Concentration-response curves were obtained with noradrenaline. Noradrenaline ($10^{-9} - 10^{-4}$ mol/L) was added in a cumulative manner until a maximal response was achieved. After the addition of each dose, a plateau response was obtained before the addition of a subsequent dose. Cumulative relaxation curves to acetylcholine (Ach) ($10^{-8} - 10^{-4}$ mol/L) and sodium nitroprusside (SNP) ($10^{-8} - 10^{-4}$ mol/L) were obtained in each strip precontracted submaximally (approximately EC$_{90}$, $10^{-5}$ mol/L) by addition of noradrenaline. Concentration-response curves were obtained with KCl. KCl (20, 40, 60 and 80 mmol/L) was added in a cumulative manner until a maximal response was achieved. After the addition of each dose, a plateau response was obtained before the addition of a subsequent dose.

At the end of each experiment, tissue was blotted dry, measured and weighed.

**Data Analysis**

Contractile responses to noradrenaline, KCl and relaxations to Ach (Inh.%) and SNP were calculated as the increase (and decrease for Ach and SNP) in tension (mg) in response to the agonist per mg of aorta. Agonist $pD_2$ value ($= -\log EC_{50}$) was calculated from each agonist concentration-response curve by linear regression analysis of the linear portion of the curve and taken as a measure of the sensitivity of the tissues to each agonist. All values are expressed as (mean ± SE). Statistical analysis of the data was performed using one-way analysis of variance (ANOVA) followed by Tukey–Kramer Multiple comparisons test. $p < 0.05$ was considered as statistically significant.

**RESULTS**

**General Characteristics**

Data showing changes in body weight and final blood glucose concentration for all groups are summarized in Table I.

The body weights of diabetic rats (205 ± 7 g) were significantly lower than NC ($p < 0.001$), AG–C ($p < 0.001$) and AG+D ($p < 0.05$) rats.

Eight weeks after injection, all rats treated with STZ exhibited severe hyperglycaemia and their blood glucose levels (583 ± 8 mg/dl) were significantly higher than those of NC ($p < 0.001$), AG–C ($p < 0.001$) and AG+D ($p < 0.001$) rats.

Water intakes and AG dosages were also shown in Table I.

**Agonist-induced Contractions**

The contractile responses of aortic strips from all groups are shown in Tables II and III. There were no significant differences in contractile responses, either $pD_2$ or $E_{\text{max}}$ values, of aortic
<table>
<thead>
<tr>
<th>Groups</th>
<th>Water intake (ml/day)</th>
<th>AG dosage (mg/kg/day)</th>
<th>Body weights (g)</th>
<th>Blood glucose (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Basal 3. day 8. week</td>
<td>Basal 3. day 8. week</td>
</tr>
<tr>
<td>Normal Control (NC)</td>
<td>44 ± 1</td>
<td>-</td>
<td>306 ± 13 307 ± 13 331 ± 14</td>
<td>111 ± 3 124 ± 5 124 ± 3</td>
</tr>
<tr>
<td>Diabet Control (DC)</td>
<td>155 ± 31,2</td>
<td>-</td>
<td>224 ± 7 239 ± 6 205 ± 73</td>
<td>99 ± 2 313 ± 526,7 583 ± 85,12-14</td>
</tr>
<tr>
<td>AMNG-Control (AG - C)</td>
<td>41 ± 1</td>
<td>79 ± 3</td>
<td>313 ± 9 315 ± 11 315 ± 14</td>
<td>108 ± 4 128 ± 4 135 ± 5</td>
</tr>
<tr>
<td>AMNG-treated diabet (AG + D)</td>
<td>150 ± 33,4</td>
<td>95 ± 5</td>
<td>229 ± 15 226 ± 15 253 ± 6</td>
<td>110 ± 4 285 ± 489,10 480 ± 1411,15,16</td>
</tr>
</tbody>
</table>

1DC vs. NC p < 0.001; 2DC vs. AG - C p < 0.001; 3AG + D vs. NC p < 0.001; 4AG + D vs. AG - C p < 0.001; 58.week vs. 3. day p < 0.01; 63.day vs. basal p < 0.001; 73.day vs. 8. week p < 0.001; 88.week vs. basal p < 0.001; 93.day vs. basal p < 0.001; 103.day vs. 8.week p < 0.001; 118.week vs. basal p < 0.001; 12DC vs. NC p < 0.001; 13DC vs. AG - KC p < 0.001; 14DC vs. AG + D p < 0.001; 15AG + D vs. NC p < 0.001; 16AG + D vs. AG - C p < 0.001.
TABLE II  pD2 values in aortas from AMNG-treated and untreated control and diabetic rats

<table>
<thead>
<tr>
<th>Groups</th>
<th>pD2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NA</td>
</tr>
<tr>
<td>Normal Control (NC)</td>
<td>7.89 ± 0.20</td>
</tr>
<tr>
<td>Diabet Control (DC)</td>
<td>7.29 ± 0.46</td>
</tr>
<tr>
<td>AMNG-Control (AG – C)</td>
<td>7.15 ± 0.18</td>
</tr>
<tr>
<td>AMNG-treated diabet (AG + D)</td>
<td>8.27 ± 0.28</td>
</tr>
</tbody>
</table>

TABLE III  Maximum contractions to NA and KCl and maximum relaxations to Ach and SNP in diabetic and control rats

<table>
<thead>
<tr>
<th>Groups</th>
<th>E_max (mg tension/mg wet weight)</th>
<th>% Max. relaxation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NA</td>
<td>KCl</td>
</tr>
<tr>
<td>Normal Control (NC)</td>
<td>467 ± 29</td>
<td>237 ± 8</td>
</tr>
<tr>
<td>Diabet Control (DC)</td>
<td>425 ± 38</td>
<td>250 ± 20</td>
</tr>
<tr>
<td>AMNG-Control (AG – C)</td>
<td>356 ± 15</td>
<td>221 ± 10</td>
</tr>
<tr>
<td>AMNG-treated diabet (AG + D)</td>
<td>342 ± 24</td>
<td>225 ± 5</td>
</tr>
</tbody>
</table>

1 DC vs. NC p < 0.001; 2 NC vs. AG – C p < 0.01; 3 DC vs. AG + D p < 0.01.

TABLE IV  The fast, slow and total components of contraction induced by noradrenaline in all the experimental groups

<table>
<thead>
<tr>
<th>Groups</th>
<th>Total</th>
<th>Fast</th>
<th>Slow</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal Control (NC)</td>
<td>450 ± 34</td>
<td>275 ± 20</td>
<td>175 ± 16</td>
</tr>
<tr>
<td>Diabet Control (DC)</td>
<td>397 ± 54</td>
<td>232 ± 31</td>
<td>165 ± 25</td>
</tr>
<tr>
<td>AMNG-Control (AG – C)</td>
<td>370 ± 22</td>
<td>233 ± 18</td>
<td>137 ± 11</td>
</tr>
<tr>
<td>AMNG-treated diabet (AG + D)</td>
<td>333 ± 26</td>
<td>216 ± 14</td>
<td>117 ± 13</td>
</tr>
</tbody>
</table>

strips to NA and KCl. In addition, as shown in Table IV, either fast or slow components of responses to noradrenaline were not significantly different among all the experimental groups.

**Agonist-induced Relaxations**

The acetylcholine-mediated relaxation (pD2 and %Max. Relax.) of aortic strips precontracted with NA is shown in Tables II and III. Either the diabetic state or AMNG treatment had no effect upon the pD2 pattern of relaxations in all groups. In contrast, the maximum relaxations generated by aortic strips from diabetic rats to Ach were markedly smaller (p < 0.001) than those generated by corresponding control tissues (NC) from age-matched rats. Treatment of diabetic animals with AMNG prevented the diabetes-induced depression of relaxations to Ach (DC vs. AG + D, p < 0.01).

Table II illustrates the pD2 values for SNP from all groups. It was observed that there were no differences in the pD2 values among all the experimental groups.

**DISCUSSION**

Vascular deterioration is one of the complicating features of human and experimental diabetes and hyperglycaemia is the primary cause of diabetic micro and macro vascular complications. There are several variables which
should perhaps be considered when comparing results: strain of rat employed, drug employed to induce diabetes, duration of diabetes, age of animals, presence or absence of endothelium, and the method used to calculate maximum response.\textsuperscript{[10–14, 19, 20]}

It has been shown that hyperglycaemia which is one of the most important markers of diabetes, caused tissue damage with several mechanisms, including advanced glycation end product (AGE) formation, increased polyol pathway flux, apoptosis and reactive oxygen species (ROS) formation.\textsuperscript{[3, 8, 9, 21]} Endothelial dysfunction and impaired endothelium-dependent relaxations have been consistently demonstrated with the histologic and experimental studies in animal models of diabetes mellitus.\textsuperscript{[19, 22–27]} The present results also demonstrated that in aortas from STZ-diabetic rats, the endothelium-dependent relaxant responses to Ach (25 ± 5%) was significantly decreased compared with NC (74 ± 4%, \( p < 0.001 \)) rats. Relaxation in the AMNG treated-diabetic group (AG+D) was significantly greater than that seen in the diabetic control (DC) group and % Max. Relax. values returned to near-control values (NC) (58 ± 8%). Our results are in agreement with the majority of previous studies\textsuperscript{[22, 23–27]} although others have reported no difference in vascular responsiveness to Ach in diabetic rats.\textsuperscript{[28, 29]} The endothelium-dependent relaxant responses to agents such as acetylcholine are largely due to release of endothelium derived relaxing factor (EDRF).\textsuperscript{[30]} EDRF is now considered to be identical to nitric oxide which is a key transducer of the vasodilator signaling.\textsuperscript{[30, 31]} Impaired endothelium-dependent relaxation in STZ-induced diabetic rats might be due to increased blood glucose level, decreased blood insulin level, decreased influx of Ca\(^{2+}\) into endothelium or decreased release of Ca\(^{2+}\) from its storage sites, a decreased content or inactivation of NO syntase and decreased diffusion of NO into the smooth muscle.\textsuperscript{[58]} In addition, diabetes is believed to cause endothelial damage via oxidative stress which induces ROS and lipid peroxidation and a diabetes-induced functional change in vascular endothelial cells could be a key event in the development of the altered endothelium-dependent vasoreactivity.\textsuperscript{[32, 33]}

AMNG used in this study is a potential therapeutic agent for preventing the generation of advanced glycation end products in diabetes mellitus.\textsuperscript{[34]} Although Crinjns et al. (1998) have reported no beneficial effect of AMNG-treatment,\textsuperscript{[45]} Bucala et al. (1991) previously demonstrated that acceleration of the advanced glycosylation process \textit{in vivo} results in a time-dependent impairment in endothelium-dependent relaxation and inhibition of advanced glycosylation with aminoguanidine prevents nitric oxide quenching, and ameliorates the vasodilatory impairment.\textsuperscript{[35]} These results agree with our findings. In addition, a number have suggested that AGEs decrease NO and cGMP levels and vascular mechanical properties and AMNG-treatment ameliorates this disturbances.\textsuperscript{[35, 36, 38]} On the other hand, AMNG could increase the release of vasodilator substances such as prostacyclin,\textsuperscript{[37]} and inhibit ROS formation\textsuperscript{[17]} and oxidant-induced apoptosis.\textsuperscript{[18]} An alternative explanation for beneficial effect of AMNG is its role on the polyol pathway. It has been shown that polyol pathway is related with the deficit for endothelium-dependent relaxation and aldose reductase inhibitors can prevent this deficit in aorta from STZ-diabetic rats\textsuperscript{[13]} and Kumari et al., have recently demonstrated that AMNG is an aldose reductase inhibitor.\textsuperscript{[39, 40]}

The majority of previous studies showed that the responsiveness to the endothelium-independent vasodilator, SNP, is not impaired in diabetics \textit{versus} control\textsuperscript{[33, 43–46]} whilst some has demonstrated an impaired response.\textsuperscript{[41, 42]} This study have also showed an unchanged sensitivity and a maximum relaxation to SNP in diabetics. Our results agree with the majority of previous studies.\textsuperscript{[33, 43–46]}

The contractile response of the rat aorta to noradrenaline, a nonselective alpha agonist, is biphasic, consisting of a fast and a slow component.\textsuperscript{[47]} The fast component of the
contraction induced by noradrenaline is a consequence of activation of alpha-1 adrenoceptors and has been demonstrated to be due to mobilisation of intracellular calcium whereas the slow component reflects activation of alpha-2 adrenoceptors and is directly dependent upon an influx of extracellular calcium.\textsuperscript{[48, 49]} Despite the controversy concerning the effects of diabetes on the maximal response, sensitivity, fast and slow components of response to the alpha-adrenoceptor agonist, such as noradrenaline,\textsuperscript{[49 – 52]} most studies agree that agonist potency is not altered by diabetes.\textsuperscript{[20, 53 – 55]} The present study has also demonstrated an unchanged sensitivity, a maximum contraction and its components to noradrenaline in diabetes. Our results are in agreement with some of the previous studies.\textsuperscript{[20, 53, 54, 55]} The discrepancy between our results and those of other groups may be due to the different experiment protocols. In the present study, there were also no significant differences between the diabetic tissues and control tissues in the responsiveness to KCl. However, although some authors found conflicting results,\textsuperscript{[56, 57]} the present results agree with those of other groups.\textsuperscript{[28, 54]}

In conclusion, our study demonstrates that the chronic AMNG-treatment reversed the diminished vascular relaxation. However, its exact mechanism of action remain unclear and requires further investigation.

**Acknowledgement**

This work was supported by the Research Fund of University of Istanbul, Project number: 1116/010598.

**References**


Submit your manuscripts at http://www.hindawi.com